Login Register Cart 0
Generic placeholder image

Current Analytical Chemistry

Editor-in-Chief

ISSN (Print): 1573-4110
ISSN (Online): 1875-6727

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Stability Indicating Analytical Method, Characterization of Degradation Impurity by UPLC-Q-TOF-MS/MS, and Establishment of Degradation Mechanism of Evodiamine

Author(s): Daya Raju Adye, Amit Kumar Sahu, Niraj Rajput, Niraj Kumar Panday and Pinaki Sengupta*

Volume 19, Issue 6, 2023

Published on: 12 July, 2023

Page: [497 - 507] Pages: 11

DOI: 10.2174/1573411019666230622150127

Price: $65

Abstract

Aim: The current research aims to establish a stability-indicating analytical method (SIAM) for the quantification of evodiamine (EVO), characterization of its degradation impurity, and establishment of possible degradation pathways.

Background: None of the degradation impurities of EVO is known and the mechanism of their formation has not been reported in any literature to date. Moreover, a SIAM for EVO is not available in any public domain.

Objective: The objective of this study is to characterize the degradation impurity of EVO by LC-MS/MS, proposing its molecular structure, identifying possible degradation pathways of generation of its impurity, and establishing a SIAM.

Method: To assist future product development, a degradation study of EVO was performed and an RPHPLC- based SIAM was developed. The major degradation product was characterized by LC-Q-TOFMS/ MS. In addition, in silico toxicity prediction was performed using the ProTox-ІI toxicity predictor.

Result: The method was found to be linear, accurate, precise, and robust over the range of 12.5 to 100 μg /mL of EVO. The method met all the acceptance criteria as specified in the ICH guideline. Only one degradation product (9% of the drug area) of EVO was generated in acidic hydrolytic conditions. The degradation product was found to be potentially inactive for hepatotoxicity and immunotoxicity, with a confidence score of more than 0.7 (70%). Moreover, the confidence score for carcinogenicity, mutagenicity, and cytotoxicity was less than 0.7, indicating it was moderately inactive for these toxicities.

Conclusion: The molecule was found to be stable in the majority of the tested stress conditions. However, the degradation product generated in acidic hydrolytic stress was characterized using LC-Q-TOF-MS/MS, which was unknown to date. The novelty of this research can be justified by the unavailability of any SIAM of EVO and the absence of any report on its susceptibility to degradation in the presence of different potential stressors. Moreover, the potential toxicity of the molecule and its impurity was not known previously. The reported degradation impurity may be useful to set the quality control acceptance criteria for EVO. Additionally, pharmaceutical industries and research laboratories may use the developed method for the analysis of quality control and stability samples of EVO.

Keywords: Evodiamine, stability indicating analytical method, degradation impurity characterization, degradation mechanism, LC-Q-TOF-MS/MS, HPLC.

« Previous
Graphical Abstract

[1]
Bakshi, M.; Singh, S. Development of validated stability-indicating assay methods—critical review. J. Pharm. Biomed. Anal., 2002, 28(6), 1011-1040.
[http://dx.doi.org/10.1016/S0731-7085(02)00047-X] [PMID: 12049968]
[2]
Sengupta, P.; Chatterjee, B.; Tekade, R.K. Current regulatory requirements and practical approaches for stability analysis of pharmaceutical products: A comprehensive review. Int. J. Pharm., 2018, 543(1-2), 328-344.
[http://dx.doi.org/10.1016/j.ijpharm.2018.04.007] [PMID: 29635054]
[3]
Singh, S.; Handa, T.; Narayanam, M.; Sahu, A.; Junwal, M.; Shah, R.P. A critical review on the use of modern sophisticated hyphenated tools in the characterization of impurities and degradation products. J. Pharm. Biomed. Anal., 2012, 69, 148-173.
[http://dx.doi.org/10.1016/j.jpba.2012.03.044] [PMID: 22521633]
[4]
Rahim, S.; Ullah, R.; Tuzen, M.; Ullah, S. Sarı A.; Saleh, T.A. Synthesis of alumina-carbon framework for efficient sorption of methyl orange from wastewater with factorial design and mechanisms. Groundw. Sustain. Dev., 2023, 22, 100950.
[http://dx.doi.org/10.1016/j.gsd.2023.100950]
[5]
Center for Drug Evaluation and Research. Q1A(R2) Stability Testing of New Drug Substances and Products. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1ar2-stability-testing-new-drug-substances-and-products
[6]
Naidu, K.R.; Kale, U.N.; Shingare, M.S. Stability indicating RP-HPLC method for simultaneous determination of amlodipine and benazepril hydrochloride from their combination drug product. J. Pharm. Biomed. Anal., 2005, 39(1-2), 147-155.
[http://dx.doi.org/10.1016/j.jpba.2005.04.001] [PMID: 15939562]
[7]
Sharma, M.K.; Pandey, K.; Shah, R.P.; Kumar, D.; Sengupta, P. A mechanistic explanation on degradation behavior of flibanserin for identification and characterization of its potential degradants using LC-DAD/ESI/APCI-Q-TOF-MS/MS. Microchem. J., 2021, 167, 106281.
[http://dx.doi.org/10.1016/j.microc.2021.106281]
[8]
Sahu, A.K.; Goswami, A.; Kate, A.S.; Sengupta, P. Identification and structural characterization of potential degraded impurities of ribociclib by time of flight -tandem mass spectrometry, and their toxicity prediction. J. Pharm. Biomed. Anal., 2021, 197, 113933.
[http://dx.doi.org/10.1016/j.jpba.2021.113933] [PMID: 33588298]
[9]
Rajput, N.; Soni, F.; Sahu, A.K.; Jadav, T.; Sharma, S.; Sengupta, P. Degradation kinetics and characterization of major degradants of binimetinib employing liquid chromatography-high resolution mass spectrometry. J. Pharm. Biomed. Anal., 2022, 215, 114753.
[http://dx.doi.org/10.1016/j.jpba.2022.114753] [PMID: 35447490]
[10]
Pokar, D.; Sahu, A.K.; Sengupta, P. LC-Q-TOF-MS driven identification of potential degradation impurities of venetoclax, mechanistic explanation on degradation pathway and establishment of a quantitative analytical assay method. J. Anal. Sci. Technol., 2020, 11(1), 54.
[http://dx.doi.org/10.1186/s40543-020-00252-4]
[11]
Rebhun, J.F.; Roloff, S.J.; Velliquette, R.A.; Missler, S.R. Identification of evodiamine as the bioactive compound in evodia (Evodia rutaecarpa Benth.) fruit extract that activates human peroxisome proliferator-activated receptor gamma (PPARγ). Fitoterapia, 2015, 101, 57-63.
[http://dx.doi.org/10.1016/j.fitote.2014.12.009] [PMID: 25542684]
[12]
Shyu, K.G.; Lin, S.; Lee, C.C.; Chen, E.; Lin, L.C.; Wang, B.W.; Tsai, S.C. Evodiamine inhibits in vitro angiogenesis: Implication for antitumorgenicity. Life Sci., 2006, 78(19), 2234-2243.
[http://dx.doi.org/10.1016/j.lfs.2005.09.027] [PMID: 16280136]
[13]
Yang, F.; Shi, L.; Liang, T.; Ji, L.; Zhang, G.; Shen, Y.; Zhu, F.; Xu, L. Anti-tumor effect of evodiamine by inducing Akt-mediated apoptosis in hepatocellular carcinoma. Biochem. Biophys. Res. Commun., 2017, 485(1), 54-61.
[http://dx.doi.org/10.1016/j.bbrc.2017.02.017] [PMID: 28189683]
[14]
Sun, H.Z.; Fang, Z.Z.; Cao, Y.F.; Sun, X.Y.; Hong, M. Investigation of the in vitro metabolism of evodiamine: C Characterization of metabolites and involved cytochrome p450 isoforms. Phytother. Res., 2013, 27(5), 705-712.
[http://dx.doi.org/10.1002/ptr.4766] [PMID: 22767428]
[15]
Wang, C.; Yue, F.; Ai, G.; Yang, J. Simultaneous determination of evodiamine and its four metabolites in rat plasma by LC-MS/MS and its application to a pharmacokinetic study. Biomed. Chromatogr., 2018, 32(7), e4219.
[http://dx.doi.org/10.1002/bmc.4219] [PMID: 29470848]
[16]
Shyr, M.H.; Lin, L.C.; Lin, T.Y.; Tsai, T.H. Determination and pharmacokinetics of evodiamine in the plasma and feces of conscious rats. Anal. Chim. Acta, 2006, 558(1-2), 16-21.
[http://dx.doi.org/10.1016/j.aca.2005.11.045]
[17]
Wen, D.; Li, C.; Liu, Y.; Liao, Y.; Liu, H. Determination of evodiamine and rutecarpine in human serum by liquid chromatography–tandem mass spectrometry. Anal. Bioanal. Chem., 2006, 385(6), 1075-1081.
[http://dx.doi.org/10.1007/s00216-006-0493-3] [PMID: 16724219]
[18]
Xia, Y.Y.; Xu, H.Y.; Cai, Y.Y.; Si, D.Y.; Liu, C.X. Simultaneous determination of evodiamine and evodine in Beagle dog plasma using liquid chromatography tandem mass spectrometry. J. Asian Nat. Prod. Res., 2013, 15(3), 235-243.
[http://dx.doi.org/10.1080/10286020.2012.762357] [PMID: 23418678]
[19]
Lin, C.; Pan, X.; Li, W.; Ma, J.; Pan, J.; Cai, J.; Wang, X.; Lin, G. Simultaneous determination of evodiamine and rutecarpine in rabbit plasma by LC-ESI-MS and its application to pharmacokinetics. Pharmazie, 2011, 66(12), 920-923.
[PMID: 22312694]
[20]
Shi, X.; Sun, F.; Liu, H.; Yan, H.; Bai, L. Extraction and determination of evodiamine from euodia fructus with SPE-HPLC based on a homemade phenyl-based monolithic cartridge. J. Chromatogr. Sci., 2022, bmac062.
[http://dx.doi.org/10.1093/chromsci/bmac062] [PMID: 35870202]

Rights & Permissions Print Cite
Article Metrics
31
2
© 2024 Bentham Science Publishers | Privacy Policy